Jianming Yu
Founder, Managing Partner @ Advantech Capital
Beijing, China
Jianming Yu is a seed investor at Advantech Capital in Beijing focused on Health Care and iOS. Jianming Yu is the current Founder of Redview Capital. Jianming attended Northwestern University - Kellogg School of Management.
- Total investments:
- 2
- Last investment:
- Lead investor:
- 50%
Last updated:
For AI agents: llms.txt
Industries Jianming Yu invests in
Stages Jianming Yu invests in
Countries Jianming Yu invests in
Contacts
| Type | Contact | Validation |
|---|---|---|
| Work email | ||
| Personal email | ||
| Work phone | ||
| Personal phone | ||
| Socials |
Investment Focus
Industry
- Health Care 2 (100%)
- iOS 1 (50%)
- Apps 1 (50%)
- Software 1 (50%)
- Biotechnology 1 (50%)
Stage
- Seed 1 (50%)
- Series B 1 (50%)
Country
- China 1 (50%)
- United States 1 (50%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| FIGUR8 is an MIT spin-off company, creating the most advanced wearable musculoskeletal (MSK) technology on the market. The solution combines Smart Biosensors, Intuitive Software and AI to analyze and advance musculoskeletal health. Our solution accurately pinpoints the source of MSK pathology and provides essential data to enhance patient-centricrecovery. Value is recorded across the entire episode of care, from injury through full recovery. FIGUR8 technology aids in significantly reducing the cost of care, improving access, and empowering patients to take control of their personal MSK health. | $4.5M / Seed / Aug 27, 2019 | ||
| Zai Lab is an innovative biopharmaceutical company based in Shanghai focused on bringing transformative medicines for cancer, autoimmune and infectious diseases to patients in China and around the world.Since their founding in 2014, their experienced team has secured partnerships with leading global biopharma companies, generating a broadpipeline of innovative drug candidates.They see theirselves as the trusted partner of choice for global biopharmaceutical companies seeking to access the Chinese market. Leveraging their team’s extensive global drug development expertise, combined with their demonstrated understanding of the pharmaceutical industry, the increasingly favorable clinical and regulatory environment in China and their in-house manufacturing capabilities, they plan to continue to secure relationships with global pharmaceutical companies to further expand their pipeline and foster innovation in China.Their team is passionate about bringing transformative new medicines to patients. Their vision is to become a fully integrated biopharmaceutical company, discovering, developing, manufacturing and commercializing their partner’s and their own products in China and around the world. To that end, they have built manufacturing capabilities to support the clinical and commercial production of their drug candidates in China, and they expect to have further clinical production capabilities in the near future. Their team is planning to establish a specialized commercial team to support marketing of their products in China and beyond, and they are expanding their discovery efforts both internally and through collaborations with leading academic institutions. | $106.2M / Series B / Jan 08, 2016 |
Co-Investors
About Advantech Capital
Advantech Capital is a private equity fund, focused on innovation-driven growth capital in China.
Advantech Capital Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Hebert Kee Chan Pang
Director
|
|||
Jennifer Jin
Partner
|
|||
Benjamin Qiu
Partner
|
|||
Jianming Yu
Founder, Managing Partner
|
|||
|
Jianming Yu
Founder, Managing Partner
|
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does Jianming Yu invest in?
Jianming Yu invests primarily in Health Care, iOS and Apps startups, most often at Seed and Series B stage. Most of the 2 investments tracked by Shizune back companies in China. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Jianming Yu?
Public channels for Jianming Yu include LinkedIn. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
When did Jianming Yu last invest?
The most recent investment recorded for Jianming Yu closed in Aug 2019. Shizune tracks 2 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
